Wednesday Dec 4
Endocyte CEO Unloads $36,000 in Stock
Endocyte CEO P Ron Ellis sold 3,000 shares of Endocyte stock in a transaction dated Monday, December 2nd.
Endocyte Receives New Coverage from Analysts at Piper Jaffray
The firm set an "overweight" rating and a $17.00 price target on the stock. Piper Jaffray's target price would suggest a potential upside of 47.31% from the company's current price.
Endocyte, Inc. To Present At The Piper Jaffray 25th Annual Health Care Conference
Endocyte, Inc. , a biopharmaceutical company and leader in developing targeted small molecule drug conjugates and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that Ron Ellis, Endocyte's president and CEO, will present at the Piper Jaffray 25th Annual Health Care Conference on Tuesday, Dec.
WLFI-TV West Lafayette
Business booms for WL cancer drug maker
It's no secret the side effects of many cancer treatments can be very debilitating.
The Star Press
BSU Foundation's endowment up
The Ball State University Foundation's endowment grew to $172 million in fiscal year 2013, up from $159 million the year before, thanks largely to a higher-than-average investment return of 13.4 percent.
Colin Goddard, Ph.D., Joins the Endocyte Board of Directors
Endocyte, Inc. , a biopharmaceutical company and leader in developing targeted small molecule drug conjugates and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that Colin Goddard, Ph.D. has joined Endocyte's board of directors.
The Indianapolis Star
Angie's List, Endocyte named to Deloitte Technology Fast 500 list
Two Indiana companies were named in the Deloitte Technology Fast 500, an annual ranking of some of the fastest-growing technology companies in the country.